Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Current Deferred Revenue (2016 - 2025)

Veracyte's Current Deferred Revenue history spans 12 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 30.66% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 30.66%, while the annual FY2025 figure was $1.2 million, 30.66% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.2 million at Veracyte, up from $417000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $4.9 million in Q1 2022 and bottomed at $417000.0 in Q3 2025.
  • The 5-year median for Current Deferred Revenue is $2.2 million (2023), against an average of $2.3 million.
  • The largest annual shift saw Current Deferred Revenue surged 1152.29% in 2021 before it tumbled 79.49% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $4.6 million in 2021, then tumbled by 43.76% to $2.6 million in 2022, then dropped by 23.15% to $2.0 million in 2023, then fell by 16.68% to $1.7 million in 2024, then crashed by 30.66% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Current Deferred Revenue are $1.2 million (Q4 2025), $417000.0 (Q3 2025), and $1.4 million (Q2 2025).